In conclusion, we have observed that clomiphene therapy to treat hypogonadism in men can result in a significant reduction in serum IGF-1 levels in some patients, which could contribute to several clinical consequences including fatigue, increased insulin resistance and adipocyte mass, reduced lean muscle and bone mass as well as reduced quality of life. The gene discussed is INS; the disease is hypogonadism.